Quoin Pharmaceuticals, Ltd.
No SEC Form 4 filings for $QNRX in the last 30 days.
See all $QNRX insider activity →Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
Quoin Pharmaceuticals (QNRX) shares rose 45% in pre-market trading after reporting positive interim data for QRX003 in a Netherton Syndrome study and a $50M private placement. The study met primary and secondary endpoints, with no serious adverse events. The financing will support operations into 2029.
Quoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million August 28, 2026 ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical com
Over the past 7 days, alphai's AI scored 5 news stories mentioning QNRX (Quoin Pharmaceuticals, Ltd.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent QNRX coverage spans technology, market movers and corporate actions.
Positive data and sizable financing could accelerate development and drive near‑term price appreciation.
Clinical data de‑risk the program and the financing extends runway, likely supporting a near‑term price rally.
The financing adds significant liquidity, likely supporting the clinical program and reducing dilution concerns.
Significant upside potential from trial data and new capital.
Positive trial data suggests a potential FDA‑first therapy, likely fueling further upside.
alphai scores every news story that mentions QNRX with an AI model for sentiment and relevance, and aggregates insider trades from Quoin Pharmaceuticals, Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
3 min readQuoin Pharmaceuticals (QNRX) shares rose 45% in pre-market trading after reporting positive interim data for QRX003 in a Netherton Syndrome study and a $50M private placement. The study met primary and secondary endpoints, with no serious adverse events. The financing will support operations into 2029.
2 min readQuoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million August 28, 2026 ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical com
2 min readU.S. stocks were mixed on Friday, with the Dow up 0.19% and the NASDAQ down 0.01%. The Chicago PMI fell to 47.1 in August, missing estimates. Quoin Pharmaceuticals (QNRX) rose 43% after positive clinical trial results and financing news. BioXcel Therapeutics (BTAI) dropped 73% after filing for bankruptcy.
2 min readQuoin Pharmaceuticals (QNRX) reported positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome. Four of six patients showed significant improvement. The company expects to complete recruitment by the end of 2026 and report topline data in Q2 2027. If approved, QRX003 could be the first FDA-approved treatment for the condition. QNRX shares rose 55% to $7.99 in pre-market trading.
2 min readQuoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Changes to 401(k) Plan Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held its 2026 Annual General Meeting of S
1 min readQuoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Com
6 min readQuoin Pharmaceuticals said the FDA cleared its IND for QRX003 to start a Phase II trial for Peeling Skin Syndrome. The study is expected to begin in 2H 2026, enrolling 6 to 8 patients in the US and Europe. Patients will apply the topical lotion twice daily to over 80% of body surface for 52 weeks. Quoin targets approval in 2028.
3 min readQuoin Pharmaceuticals (QNRX) said the FDA cleared its IND for QRX003 in Peeling Skin Syndrome, allowing it to start a planned Phase 2 trial. The study is expected to begin in 2H 2026, enrolling 6-8 patients and dosing twice daily for 52 weeks. The company cited no FDA safety concerns and prior investigator-led pediatric results showing improvements by Week 12.
3 min readQuoin Pharmaceuticals (NASDAQ: QNRX) said it has completed a wholly owned Japan subsidiary to prepare for direct commercialization of QRX003 for Netherton Syndrome, if approved. The move follows Japan’s MHLW granting Orphan Drug Designation to QRX003. QRX003 is in Phase 2; Phase 3 is expected to start H2 2026 with a potential NDA filing in 2027.
2 min read
